Acute endovascular reperfusion therapy in ischemic stroke: a systematic review and meta-analysis of randomized controlled trials.

This study was aborted because of approval of intravenous infusion of recombinant tissue plasminogen activator in Japan and the primary outcome, the proportion of patients with favorable outcomes (mRS scores of 0 to 2) at 90 days did not reach statistical significance.[ 2 ] Since 2004 several mechanical thrombectomy devices have been approved by government regulatory authorities according to the results of the non-randomized studies.[ 3 – 7 ].

also in 111,027 other papers